줄기세포 및 재생 치료 시장

The global market for stem cell and regenerative therapy is projected to grow from an estimated $16.7 billion in 2025 to $43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.

The North American market for stem cell and regenerative therapy is projected to grow from an estimated $6.7 billion in 2025 to $17.4 billion by 2030, at a CAGR of 21.2% from 2025 to 2030.

The Asia-Pacific market for stem cell and regenerative therapy is projected to grow from an estimated $3.5 billion in 2025 to $10.1 billion by 2030, at a CAGR of 23.2% from 2025 to 2030.

Report Scope

The report provides an overview of the global stem cell and regenerative therapy market and analyzes market trends. The report includes global revenue (in $ millions) for the base year data (2024) and estimated data for the forecast period (2025 through 2030). The market is segmented by product and services, application and region. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with a focus on major countries in each region.

The report focuses on significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies and the patent landscape related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies in the global stem cell and regenerative medicine market, as well as a patent analysis. It also features a section with company profiles that provides overviews, key financials, product portfolios and recent developments of key market companies.

Report Includes

• 50 data tables and 62 additional tables
• Overview and an analysis of the global market for stem cell and regenerative therapy (medicines)
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, along with a corresponding market share analysis based on product and service type, application and region
• Facts and figures pertaining to global market dynamics, advancements in therapy, regulations, prospects and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Patent review, featuring key granted and published patents
• Review of emerging trends and technologies as well as new developments in the stem cell and regenerative therapy market
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives and venture fundings, and an investment outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading companies, including Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb Co., Organogenesis Inc., and MiMedx Group Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Technology Background
• Stem Cell
• Embryonic Stem Cells
• Adult Stem Cells
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Neural Stem Cell
• Endothelial Progenitor Cell
• Epithelial Stem Cell
• Very Small Embryonic-Like Cell
• Cord Blood Stem Cell
• Induced Pluripotent Stem Cells
• Cell Therapy
• A Brief History of CAR-T Cell Therapy
• FDA Product Approvals
• Gene Therapy
• Evolution of Gene Therapy
• Macroeconomic Factors Analysis
• PESTEL Analysis
• Impact of U.S. Tariff Laws on the Stem Cell and Regenerative Therapy Market
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to High)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (High)
• Threat of Substitutes (Low to Moderate)
• Competition in the Industry (High)

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Demand for Regenerative Medicines
• Increasing Research and Regulatory Approval for Tissue Engineering Products
• Rising Venture Capital Funding
• Demand for an Effective Drug Discovery and Development Process
• Rising Focus on Minimizing Animal Testing
• Market Restraints
• High Cost and Lack of Skilled Workforce
• Complex Regulatory Framework
• Market Opportunities
• Technological Advances
• Growth in iPSC Banking

Chapter 4 Regulatory Landscape

• Overview
• Gene Therapy Regulations
• Cell Therapy Regulations
• Viral and Non-Viral Vectors
• Media
• Regulatory Frameworks in the U.S.
• Regulatory Frameworks in Europe
• Cell and Gene Therapy Regulations in Europe
• Regulatory Frameworks in Asia-Pacific

Chapter 5 Emerging Technologies and New Developments

• Overview
• Reprogramming Technologies
• Gene Editing Technologies
• 3D Organoids
• Artificial Intelligence in Stem Cell Research

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Breakdown by Products and Services
• Key Takeaways
• Therapeutics
• Tools and Reagents
• Cell Banking
• Market Breakdown by Application
• Key Takeaways
• Oncology
• Orthopedic
• Diabetes
• Dermatology
• Cardiovascular Disorders
• Central Nervous System Disorders
• Others
• Geographic Breakdown
• Market Breakdown by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Leading Players in the CGT Market, 2024
• Leading Players in the Tissue Engineering Market, 2024
• Strategic Analysis

Chapter 8 Sustainability in the Stem Cell and Regenerative Therapy Market: ESG Perspective

• Sustainability: The Stem Cell and Regenerative Therapy Market
• Understanding the ESG Data
• Key ESG Issues
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 9 Patent Landscape

• Key Takeaways
• Patent Review
• Gene Therapy Patents, by Year
• Gene Therapy Patents, by Leading Applicants
• Gene Therapy Patents, by Document Type
• Cell Therapy Patents, by Year
• Cell Therapy Patents, by Leading Applicants
• Cell Therapy Patents, by Status
• Tissue Engineering Patents, by Year
• Tissue Engineering Patents, by Leading Applicants
• Tissue Engineering Patents, by Status

Chapter 10 Appendix

• Methodology
• Abbreviations
• References
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• BIOGEN
• BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
• BRISTOL-MYERS SQUIBB CO.
• CELLECTIS S.A.
• CRISPR THERAPEUTICS
• EUREKA THERAPEUTICS INC.
• GILEAD SCIENCES INC.
• MIMEDX GROUP INC.
• NOVARTIS AG
• ORGANOGENESIS INC.
• STRYKER
• TECNOSS
• ZIMMER BIOMET